Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1990 Apr 1;171(4):1205–1220. doi: 10.1084/jem.171.4.1205

Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen

PMCID: PMC2187845  PMID: 2324687

Abstract

Breaking the state of immunological unresponsiveness of tumor-bearing individuals to cancer is a prerequisite for active or passive tumor- specific immunotherapy. To study this problem the immunogenic MHC class I antigen, K216 was transfected into a progressor tumor. The transfected tumors were regularly rejected by normal mice but grew progressively in mice bearing nontransfected tumors. In addition, transgenic mice were derived to obtain normal cells and tissues expressing the same K216 gene product. Normal mice rejected K216- positive normal or malignant tissue grafts and generated K216-specific CTL in vitro and in vivo in response to these challenges. In contrast, mice bearing nontransfected tumors, though rejecting K216-positive nonmalignant tissue grafts, did not reject K216-positive tumors nor generate K216-specific CTL in response to K216-positive tumor cells. Mice bearing K216-positive tumors also rejected the nonmalignant K216- positive tissue grafts, but this in vivo response failed to lead to rejection of the simultaneously present tumor graft expressing the same antigen; in fact, immunity had no measurable effect whatsoever on tumor size or incidence and caused no selection for antigen loss variants. Taken together, the present findings suggest that transfer of expression of a target antigen into nonmalignant cells provides a way for obtaining effective stimulation of antigen-specific CTL in tumor- bearing mice, but that additional manipulations will be required to cause immunological rejection of established tumors.

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ascher N. L., Ferguson R. M., Hoffman R., Simmons R. L. Partial characterization of cytotoxic cells infiltrating sponge matrix allografts. Transplantation. 1979 Apr;27(4):254–259. doi: 10.1097/00007890-197904000-00010. [DOI] [PubMed] [Google Scholar]
  2. Berendt M. J., North R. J. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med. 1980 Jan 1;151(1):69–80. doi: 10.1084/jem.151.1.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Evans G. A., Margulies D. H., Shykind B., Seidman J. G., Ozato K. Exon shuffling: mapping polymorphic determinants on hybrid mouse transplantation antigens. Nature. 1982 Dec 23;300(5894):755–757. doi: 10.1038/300755a0. [DOI] [PubMed] [Google Scholar]
  4. Faustman D. L., Steinman R. M., Gebel H. M., Hauptfeld V., Davie J. M., Lacy P. E. Prevention of rejection of murine islet allografts by pretreatment with anti-dendritic cell antibody. Proc Natl Acad Sci U S A. 1984 Jun;81(12):3864–3868. doi: 10.1073/pnas.81.12.3864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fisher M. S., Kripke M. L. Systemic alteration induced in mice by ultraviolet light irradiation and its relationship to ultraviolet carcinogenesis. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1688–1692. doi: 10.1073/pnas.74.4.1688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fujimoto S., Greene M. I., Sehon A. H. Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts. J Immunol. 1976 Mar;116(3):791–799. [PubMed] [Google Scholar]
  7. HESLOP R. W., KROHN P. L., SPARROW E. M. The effect of pregnancy on the survival of skin homografts in rabbits. J Endocrinol. 1954 Jun;10(4):325–332. doi: 10.1677/joe.0.0100325. [DOI] [PubMed] [Google Scholar]
  8. Inaba K., Young J. W., Steinman R. M. Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells. J Exp Med. 1987 Jul 1;166(1):182–194. doi: 10.1084/jem.166.1.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. KALISS N. Immunological enhancement of tumor homografts in mice: a review. Cancer Res. 1958 Oct;18(9):992–1003. [PubMed] [Google Scholar]
  10. KLEIN G., SJOGREN H. O., KLEIN E., HELLSTROM K. E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 1960 Dec;20:1561–1572. [PubMed] [Google Scholar]
  11. Knight S. C., Hunt R., Dore C., Medawar P. B. Influence of dendritic cells on tumor growth. Proc Natl Acad Sci U S A. 1985 Jul;82(13):4495–4497. doi: 10.1073/pnas.82.13.4495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kripke M. L. Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst. 1974 Nov;53(5):1333–1336. doi: 10.1093/jnci/53.5.1333. [DOI] [PubMed] [Google Scholar]
  13. LANMAN J. T., DINERSTEIN J., FIKRIG S. Homograft immunity in pregnancy: lack of harm to the fetus from sensitization of the mother. Ann N Y Acad Sci. 1962 Oct 24;99:706–716. doi: 10.1111/j.1749-6632.1962.tb45355.x. [DOI] [PubMed] [Google Scholar]
  14. Lee D. R., Rubocki R. J., Lie W. R., Hansen T. H. The murine MHC class I genes, H-2Dq and H-2Lq, are strikingly homologous to each other, H-2Ld, and two genes reported to encode tumor-specific antigens. J Exp Med. 1988 Nov 1;168(5):1719–1739. doi: 10.1084/jem.168.5.1719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Linsk R., Vogel J., Stauss H., Forman J., Goodenow R. S. Structure and function of three novel MHC class I antigens derived from a C3H ultraviolet-induced fibrosarcoma. J Exp Med. 1986 Sep 1;164(3):794–813. doi: 10.1084/jem.164.3.794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mullen C. A., Rowley D. A., Schreiber H. Highly immunogenic regressor tumor cells can prevent development of postsurgical tumor immunity. Cell Immunol. 1989 Mar;119(1):101–113. doi: 10.1016/0008-8749(89)90227-x. [DOI] [PubMed] [Google Scholar]
  17. Mullen C. A., Urban J. L., Van Waes C., Rowley D. A., Schreiber H. Multiple cancers. Tumor burden permits the outgrowth of other cancers. J Exp Med. 1985 Nov 1;162(5):1665–1682. doi: 10.1084/jem.162.5.1665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. North R. J. Down-regulation of the antitumor immune response. Adv Cancer Res. 1985;45:1–43. doi: 10.1016/s0065-230x(08)60265-1. [DOI] [PubMed] [Google Scholar]
  19. PREHN R. T., MAIN J. M. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957 Jun;18(6):769–778. [PubMed] [Google Scholar]
  20. Philipps C., McMillan M., Flood P. M., Murphy D. B., Forman J., Lancki D., Womack J. E., Goodenow R. S., Schreiber H. Identification of a unique tumor-specific antigen as a novel class I major histocompatibility molecule. Proc Natl Acad Sci U S A. 1985 Aug;82(15):5140–5144. doi: 10.1073/pnas.82.15.5140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ross S. R., Solter D. Glucocorticoid regulation of mouse mammary tumor virus sequences in transgenic mice. Proc Natl Acad Sci U S A. 1985 Sep;82(17):5880–5884. doi: 10.1073/pnas.82.17.5880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shah P. D., Gilbertson S. M., Rowley D. A. Dendritic cells that have interacted with antigen are targets for natural killer cells. J Exp Med. 1985 Aug 1;162(2):625–636. doi: 10.1084/jem.162.2.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Stauss H. J., Linsk R., Fischer A., Watts S., Banasiak D., Haberman A., Clark I., Forman J., McMillan M., Schreiber H. Isolation of the MHC genes encoding the tumour-specific class I antigens expressed on a murine fibrosarcoma. J Immunogenet. 1986 Apr-Jun;13(2-3):101–111. doi: 10.1111/j.1744-313x.1986.tb01090.x. [DOI] [PubMed] [Google Scholar]
  24. Stauss H. J., Van Waes C., Fink M. A., Starr B., Schreiber H. Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer. J Exp Med. 1986 Nov 1;164(5):1516–1530. doi: 10.1084/jem.164.5.1516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stuart F. P., Fitch F. W., Rowley D. A. Specific suppression of renal allograft rejection by treatment with antigen and antibody. Transplant Proc. 1970 Dec;2(4):483–488. [PubMed] [Google Scholar]
  26. Urban J. L., Burton R. C., Holland J. M., Kripke M. L., Schreiber H. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med. 1982 Feb 1;155(2):557–573. doi: 10.1084/jem.155.2.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Urban J. L., Holland J. M., Kripke M. L., Schreiber H. Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation. J Exp Med. 1982 Oct 1;156(4):1025–1041. doi: 10.1084/jem.156.4.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ward P. L., Koeppen H., Hurteau T., Schreiber H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med. 1989 Jul 1;170(1):217–232. doi: 10.1084/jem.170.1.217. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES